Navigation Links
Varian, Inc. Reports First Quarter 2008 Results
Date:1/23/2008

ental information and an alternative presentation useful to investors' understanding of the company's core operating results and trends. In addition, investors have indicated to us that they analyze the benefits of acquisitions based on the cash return on the investment made, and thus consider financial measures excluding acquisition-related intangible and inventory write-up amortization as important, useful information.

We similarly believe that excluding share-based compensation expense and restructuring and other related costs (principally related to facility closures and employee terminations to improve operational efficiency) provides supplemental information and an alternative presentation useful to investors' understanding of the company's core operating results and trends, especially when comparing those results on a consistent basis to results for previous periods and anticipated results for future periods. Investors have indicated that they consider financial measures of our results of operations excluding share-based compensation expense and restructuring and other related costs as important supplemental information useful to their understanding of our historical results and estimating of our future results.

We also believe that, in excluding share-based compensation expense, acquisition-related intangible and inventory write-up amortization and restructuring and other related costs, our non-GAAP financial measures provide investors with transparency into what is used by management to measure and forecast our results of operations, to compare on a consistent basis our results of operations for the current period to that of prior periods, to compare our results of operations on a more consistent basis against that of other companies, in making financial and operating decisions and to establish certain management compensation.

Although we believe, for the foregoing reasons, that our presentation of non-GAAP financial measures provides u
'/>"/>

SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... September 19, 2014 The new , ... , available today on PharmaBoardroom.com for ... crisis that rocked the Spanish economy in 2009, and the ... community has remained pragmatic in times of trouble. ... the fifth biggest European market, and the general conditions to ...
(Date:9/18/2014)... A novel robotic system that can operate ... being tested as part of a biomedical research partnership ... the aim of determining if the robot, in conjunction ... faster, more accurate, less costly, and less discomforting for ... to deliver prostate cancer therapies with greater precision. , ...
(Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Telik, Inc.,(Nasdaq: TELK ) announced that the ... partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical trials. ... data by,the agency and permits the resumption of ... Alto, CA is a biopharmaceutical company focused on,discovering, ...
... Show Lower Dose Associated with Fewer Adverse Events in Healthy ... ... ,GlaxoSmithKline,s (NYSE: GSK ) HIV protease inhibitor LEXIVA(R),(fosamprenavir calcium) may now ... level of protease inhibitors in the,bloodstream. The U.S. Food and Drug ...
... Standards, HOFFMAN ESTATES, Ill., Oct. 12 ... which failed quality testing,ConsumerLab.com anonymously purchased, tested and ... CNCA, a leading national distributor,of premium dietary supplements ... health and wellness., "ConsumerLab.com testing showed that ...
Cached Biology Technology:FDA Removes Partial Hold on TELCYTA Clinical Development 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 2CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 3
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... who initially survive a heart attack, a significant cause of ... literally, bursting of the heart wall. A new ... as the key player in the biochemical cascade that leads ... Advance Online Publication (AOP) of the journal Nature Medicine, ...
... new study, led by PRBO Conservation Science (PRBO), projects a ... sea-level rise scenarios that are increasingly likely. PRBO and ... San Francisco Bay,s tidal marsh could be lost in the ... sea-level rise, low sediment availability and no significant restoration]. ...
... are started in-ground, then sold as bare-root ,liners, to ... To minimize wind damage and to facilitate transport from ... buried deeper than necessary. This deep planting of liners ... important foundations of root systems responsible for trees, health ...
Cached Biology News:Study explains how heart attack can lead to heart rupture 2Study explains how heart attack can lead to heart rupture 3Bleak future for Bay area tidal marshes? 2Bleak future for Bay area tidal marshes? 3Bleak future for Bay area tidal marshes? 4Planting depth's effect on container-grown trees 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: